Testing three medicines for advanced stomach cancer after first treatment
Part of Cancer clinical trials.
This study tests whether a combination of ramucirumab, nal-IRI (irinotecan liposome), and trifluridine/tipiracil can work better as a second treatment for metastatic stomach cancer. It may help people whose cancer has returned or progressed after only one prior treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic stomach cancer confirmed by biopsy or fluid test (adenocarcinoma).
- You’ve only had one prior set of cancer medicines (first-line). It must have stopped working or returned during adjuvant therapy, or within 6 months after finishing it.
- You can do most daily activities (ECOG performance status 0 or 1).
- If your tumor is HER2-positive, you must have already been treated with Herceptin (trastuzumab).
- You can take medicines by mouth, and you must have at least one measurable tumor spot on scans.
- You must meet blood/organ health levels (kidney, liver, bone marrow) and have enough clotting safety (INR/PTT within limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
Hear when a new Metastatic Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.